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Background and PurposeaaElevated plasma total homocysteine (tHcy) levels are reported 
to be associated with an increased risk of Alzheimer’s disease (AD). However, the mechanism 
by which homocysteine contributes to the pathogenesis of AD is as yet unknown. The aim of 
this study was to elucidate the relationship between white matter changes (WMC) and medial 
temporal lobe atrophy (MTA) on brain magnetic resonance imaging (MRI), and plasma levels 
of tHcy in AD patients.   
MethodsaaSeventy-two patients with a clinical diagnosis of probable AD were recruited to the 
study. Plasma tHcy levels, vascular risk factors, and WMC and MTA on brain MRI were eval-
uated in all patients. The AD patients were classified into two groups: those with no or minimal 
WMC (69.2±8.8 years, mean±SD, n=36) and those with moderate-to-severe WMC (74.6±4.6 
years, n=36) on brain MRI.   
ResultsaaIn a univariate logistic regression analysis, the risk of moderate-to-severe WMC in 
AD was significantly associated with increasing age, female gender, lower education level, hy-
pertension, high plasma tHcy levels, and lower Mini-Mental State Examination (MMSE) score. 
Multivariate logistic regression analysis revealed only high plasma tHcy as the independent 
and significant risk factor for moderate-to-severe WMC [odds ratio (OR; adjusted for age, 
gender, education level, MMSE score, and hypertension comparing the top tertile - tHcy levels 
≥12.9 µmol/L - with the bottom tertile - tHcy levels ≤9.4 µmol/L)=7.35; 95% confidence in-
terval, confidence interval=1.36-39.84; p=0.02], and age as a borderline significant risk factor 
(OR=1.08, 95% CI=0.99-1.19, p=0.09) in AD patients. Plasma tHcy levels were not correlated 
significantly with either right or left MTA.   
ConclusionsaaOur results suggest that the vascular pathway mediates the association between 
elevated plasma tHcy levels and AD.  J Clin Neurol 2009;5:85-90
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Introduction 
 
Elevated plasma total homocysteine (tHcy) levels are asso-
ciated with an increased risk of clinical stroke and cardiovas-
cular disease.
1,2 Findings of previous studies have suggested 
that an elevated plasma tHcy level is associated with silent 
brain infarcts and white-matter lesions on magnetic resonance 
imaging (MRI) of the brain in healthy elderly and middle-
aged adults.
3-5 The presence of cerebral hyperintensities in 
the deep subcortical and periventricular white matter on 
brain MRI is a common finding in elderly people.
6 Subjects 
with cerebral white-matter changes (WMC) may have an 
increased risk of either ischemic or hemorrhagic stroke.
7-9 
Thus, the presence of extensive WMC may be considered an 
indicator of subclinical vascular injury. White matter lesions 
are also more common in patients with Alzheimer’s disease 
(AD) than in the nondemented elderly.
10,11 
It has recently been reported that increased plasma tHcy  
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levels are associated with an increased risk of the develop-
ment of neurodegenerative diseases such as AD, Parkinson’s 
disease, and amyotrophic lateral sclerosis.
12-14 Higher plasma 
tHcy levels appear to be associated with an increased risk of 
silent brain infarction on brain MRI,
15 and with moderate-to-
severe WMC on brain computed tomography (CT) in indivi-
duals with AD.
16 Homocysteine has been shown to potentiate 
amyloid beta-peptide-mediated toxicity in primary neuronal 
cultures.
17 However, the mechanisms underlying the associa-
tion between high plasma tHcy with AD are uncertain and 
may involve vascular or neuronal pathways, or both. 
Medial temporal lobe atrophy (MTA) on MRI is the first 
and most striking manifestation of AD.
18 MTA, which is 
correlated with Braak staging, and plaques and tangles in the 
hippocampus,
19 is an accepted measure of neuronal loss. To 
our knowledge, the association between plasma tHcy levels 
and MTA has not been studied in AD patients. 
If homocysteine increases the risk of AD via a vascular 
toxic mechanism, WMC may be associated with increased 
plasma tHcy in AD. However, if homocysteine acts in AD 
pathogenesis via a cellular toxic mechanism, a higher plasma 
tHcy may not be associated with WMC, but rather with MTA. 
The objective of this study was thus to elucidate the relation-
ship between WMC and MTA on brain MRI, and plasma 
tHcy levels in AD patients. 
 
Methods 
 
Subjects 
Seventy-two patients with AD were serially recruited in a 
memory clinic of the Department of Neurology at Inha Uni-
versity Hospital between January 2004 and October 2008. 
The participants included in the present study were those 
who met the criteria for probable AD established by the Na-
tional Institute of Neurological and Communicative Disorders 
and Stroke-Alzheimer’s Disease and Related Disorders As-
sociation,
20 and who submitted to a brain MRI and measure-
ment of plasma tHcy levels. Subjects were excluded if they 
had a history of pernicious anemia, gastric surgery, neoplasia, 
hepatorenal disease, malabsorption syndrome, or vegetaria-
nism, were taking medication associated with increased tHcy 
levels, such as thiazide, diuretics, azathioprine, phenytoin, 
and methotrexate, or had abnormally low levels of serum 
vitamin B12 and folate.
21 Subjects were also excluded if the 
time interval between the brain MRI and blood sampling for 
measuring plasma tHcy was more than 2 months. 
Blood samples were collected from the subjects after over-
night fasting, and plasma tHcy was determined by high-perfor-
mance liquid chromatography, as described elsewhere.
22 Serum 
vitamin B12 and folate levels were measured using radioim-
munoassay. The study protocol was reviewed and approved 
by the institutional review board of Inha University Hospital. 
 
Definition of vascular risk factors 
Hypertension, diabetes mellitus (DM), heart disease, hyperli-
pidemia, and smoking were evaluated in all patients. Hyper-
tension was defined as a systolic blood pressure (BP) of ≥140 
mmHg, a diastolic BP of ≥90 mmHg, or use of antihyperten-
sive medication according to the World Health Organization 
guidelines for the management of hypertension.
23 DM was 
defined based on current treatment with insulin, oral hypo-
glycemic medication, or an 8-hour fasting plasma glucose 
level of ≥126 mg/dL, as indicated by the American Diabetes 
Association.
24 For the definition of hypercholesterolemia, we 
followed the criteria established by the National Cholesterol 
Education Program-Adult Treatment Panel II based on a 
total cholesterol level of >200 mg/dL, a low-density lipopro-
tein cholesterol level of >130 mg/dL, and a high-density li-
poprotein cholesterol level of <35 mg/dL; hypertriglyceride-
mia was based on serum triglyceridemia (>200 mg/dL).
25 
Heart disease was defined based on a history of myocardiac 
infarction, angina pectoris, or heart failure, and atrial fibrilla-
tion on ECG. Patients were classified as being either current 
smokers or nonsmokers. 
 
Rating white-matter changes  and Medial tem-
poral lobe atrophy on brain MRI 
All participating patients had submitted to a brain MRI, which 
was performed on a 1.5-T superconducting magnet (Signa, 
GE Medical Systems, Milwaukee, WI, USA). Axial T1-
weighted, T2-weighted, and fluid-attenuated inversion re-
covery (FLAIR) images were obtained at a slice thickness of 
5 mm for all subjects. T1-weighted coronal images were ob-
tained in 25 subjects and T2-weighted coronal images were 
obtained in 45 subjects. The degree of WMC was rated on 
axial T2-weighted and FLAIR images by one reader who was 
blind to the clinical details, using the visual scale of Fazekas 
et al.
26 Patients were classified as having one of the following: 
1) Minimal or no WMC: If there were either no or only 
slight periventricular hyperintensities with caps or rims with 
a maximum diameter of <10 mm, and either absent or single 
lesions of <10 mm and no confluent lesions in the deep sub-
cortical white-matter area.   
2) Moderate-to-severe WMC: If there were moderate or 
severe periventricular hyperintensities with caps or rims with 
a maximum diameter of ≥10 mm, or single or grouped le-
sions ≥10 mm in any diameter in the deep subcortical white-
matter area. 
A standardized five-point scale was used to rate right- and 
left-sided MTA from T1- or T2-weighted coronal images.
18  
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The five-point scale (0=absent, 1=minimal, 2=mild, 3=mod-
erate, 4=severe) rated atrophy based on the height of the 
hippocampal formation and the width of the cerebrospinal 
fluid spaces. All scans were assessed by one rater who was 
blinded to the clinical details. 
 
Statistical analysis 
Student’s t-test was used to evaluate differences in age, 
education level, Mini-Mental State Examination (MMSE) 
score, and the levels of plasma tHcy, vitamin B12, and folate 
between AD patients with no or minimal WMC and those 
with moderate-to-severe WMC. The chi-square test was used 
to assess differences in gender, hypertension, DM, hypercho-
lesterolemia, hypertriglyceridemia, heart disease, and smoking 
habit between these two groups of AD patients. Logistic re-
gression analysis was used to assess the influence of explan-
atory variables on WMC. Using a dichotomous approach, the 
reference group comprised AD patients with no or minimal 
WMC on brain MRI. 
Plasma tHcy levels were categorized into tertiles, and odds 
ratios (ORs) were calculated by dividing the prevalence ratio 
in each tertile by the ratio in the lowest tertile in simple and 
multiple logistic regression models. We analyzed the asso-
ciation between tertiles of plasma tHcy and moderate-to-
severe WMC by multiple logistic regression adjusted for age, 
gender, education level, MMSE score, and hypertension. 
Spearman’s correlation coefficient was used to evaluate the 
association between MTA and plasma tHcy levels. 
 
Results 
 
Of the 72 AD patients recruited to the study, 36 (50%) had 
moderate-to-severe WMC and 36 (50%) had no or minimal 
WMC. The time interval between the brain MRI and blood 
sampling for measurement of plasma tHcy was 4.2±8.8 days 
(mean±SD; range 0-50 days). The demographic and clinical 
characteristics of the two groups of patients are displayed in 
Table 1. The group of AD patients with moderate-to-severe 
WMC were older on average and contained a higher propor-
tion of females than those with no or minimal WMC. The 
patients with no or minimal WMC had more years of edu-
cation, higher MMSE scores, a lower prevalence of hyperten-
sion, and lower plasma levels of tHcy than those with mod-
erate-to-severe WMC. There were no significant differences 
in the prevalences of DM, hypercholesterolemia, hypertri-
glyceridemia, heart disease, smoking habit, and levels of 
serum vitamin B12 and folate between the two groups of AD 
patients. 
In a univariate logistic regression analysis, the risk of mod-
erate-to-severe WMC was associated with increasing age 
[OR=1.12; 95% confidence interval (CI)=1.04-1.22; p=0.004] 
and hypertension (OR=3.14, 95% CI=1.20-8.24, p=0.02). 
The top tertile of plasma tHcy (≥12.9 μmol/L) was at risk of 
moderate-to-severe WMC in comparison with the bottom 
tertile (≤9.4 μmol/L; OR=4.86, 95% CI=1.43-16.50, p=0.01). 
In addition, a high education level (OR=0.83, 95% CI=0.74-
0.94, p=0.003), high MMSE score (OR=0.80, 95% CI=0.70-
0.91, p=0.001), and male gender (OR=0.18, 95% CI=0.05-
0.60,  p=0.006) showed protective effects of moderate-to-
severe WMC in AD patients (Table 2). 
Multivariate logistic regression analysis revealed only high 
plasma tHcy as an independent and significant risk factor for 
moderate-to-severe WMC in AD patients [OR (adjusted for 
age, gender, education, MMSE score, and hypertension com-
Table 1. Differences in demographic and clinical variables between AD patients with no or minimal white matter change (WMC) and those 
with moderate-to-severe WMC on brain MRI 
  White matter change 
 
All patients (n=72) 
No or minimal (n=36)  Moderate-to-severe (n=36) 
p 
Age (years) 72.0±7.50 69.2±8.80 74.6±4.6 0.002 
Males : females  19 : 53  15 : 21  4 : 32  0.003 
Education (years) 4.4±4.8 6.2±5.3 2.6±3.5 0.001 
MMSE score  17.2±4.90 19.3±4.00 15.0±4.8 <0.001< 
Hypertension (%) 52.8  38.9  66.7  0.020 
Diabetes mellitus (%)  09.7  08.3 11.1  0.690 
Hypercholesterolemia (%) 55.6  47.2  63.9  0.150 
Hypertriglyceridemia (%) 16.7  11.1  22.2  0.190 
Heart disease (%)  09.7 11.1  08.3 0.690 
Current smoker (%)  06.9  08.3  05.6 0.640 
Folate (ng/mL)  09.0±10.1 8.2±4.0  009.8±13.7 0.510 
Vitamin B12 (pg/mL) 625.6±258.4 667.7±246.2  0582.3±267.1 0.170 
Homocysteine (μmol/L) 12.1±5.00 10.8±3.5 13.3±6.0 0.030 
AD: Alzheimer’s disease, MMSE: Mini Mental State Examination.    
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paring the top tertile - tHcy levels ≥12.9 μmol/L - with the 
bottom tertile - tHcy levels ≤9.4 μmol/L)=7.35, 95% CI=1.36- 
39.84, p=0.02; Table 3]. Age had a borderline association 
with moderate-to-severe WMC in AD patients (multivariate 
logistic regression: OR=1.08, 95% CI=0.99-1.19, p=0.09). 
Education, gender, MMSE score, and hypertension were not 
significantly associated with moderate-to-severe WMC in 
AD patients (multivariate analysis using logistic regression). 
Plasma tHcy levels were not correlated significantly with 
atrophy of either the right (R=-0.06, p=0.62) or left (R=-0.07, 
p=0.54) medial temporal lobe in all AD patients. There were 
no significant correlations between right and left MTA, and 
plasma tHcy levels in any of the AD patients, regardless of 
the degree of WMC. 
 
Discussion 
 
We found an independent, cross-sectional association between 
higher plasma tHcy levels and moderate-to-severe WMC on 
brain MRI in patients with AD. This is consistent with the 
previous finding that higher plasma tHcy levels are associat-
ed with WMC on brain CT in AD patients.
16 WMC were en-
countered in 60% of the brains from autopsy-confirmed cases 
of AD, and the lesions had the characteristics of incomplete 
infarction.
10 
In the present study, older age, lower education, lower 
MMSE score, female gender, and hypertension were associ-
ated with moderate-to-severe WMC, as shown using uni-
variate logistic regression analyses. However, they were not 
associated significantly with moderate-to-severe WMC in 
multivariate analyses. In addition, older age only had a bor-
derline association with moderate-to-severe WMC (multivar-
iate analysis). The education level of the elderly is low, and 
is generally lower for female elderly than for male elderly in 
South Korea. The significant effect of lower education (uni-
variate analysis) might be due to the possible interactive 
effect with age. Since it has been shown that MMSE score is 
associated with education level,
27 the lower education level 
of the AD patients with moderate-to-severe WMC might then 
be associated with lower MMSE scores in comparison with 
those with no or minimal WMC. The group of AD patients 
with moderate-to-severe WMC was 5 years older and had 
higher proportion of females in comparison with those with 
no or minimal WMC (88.9% vs. 58.3%, respectively). The 
significant effect of being female (univariate analysis) might 
thus be due to the possible interactive effects with age and 
education. 
A recent study revealed that high plasma tHcy levels, but 
not hypertension and age, were only associated with an in-
creased risk of developing silent brain infarcts in AD.
15 WMC 
on brain CT were not associated with hypertension, but rather 
with high plasma tHcy levels.
16 A longitudinal study showed 
that BP values were high 10-15 years before the onset of AD 
or WMC on brain CT, but then decreased in the more recent 
years before dementia onset.
28 Dysfunction in central BP au-
toregulatory mechanisms due to chronic hypertension could 
lead to a reduction in cerebral blood flow at BP levels con-
sidered normal for normotensive subjects.
29 AD patients with 
moderate-to-severe WMC might have a much higher BP 
prior to the drop that occurs before the onset of AD, and a 
concomitant dysfunction of BP autoregulatory mechanisms. 
A longitudinal study is needed to evaluate the relationship 
between hypertension and WMC in AD. 
Table 2. Univariate logistic regression analysis with moderate-to-
severe white matter change as the dependent variable in AD pa-
tients 
 
Moderate-to-severe  
white matter change 
  OR  95% CI  p 
Age (years) 1.12  1.04-1.22  0.004 
Being male  0.18  0.05-0.60  0.006 
Education (years) 0.83  0.74-0.94  0.003 
MMSE score  0.80  0.70-0.91  0.001 
Hypertension 3.14  1.20-8.24  0.020 
Diabetes mellitus  1.38  0.29-6.64  0.690 
Hypercholesterolemia 2.03  0.78-5.31  0.150 
Hypertriglyceridemia 2.39  0.64-8.83  0.190 
Heart disease  0.73  0.15-3.51  0.690 
Current smoker  0.65  0.10-4.12  0.650 
Folate (ng/mL) 1.02  0.96-1.08  0.520 
Vitamin B12 (pg/mL) 1.00  0.99-1.00  0.170 
Homocysteine (μmol/L) ≤9.4  1.00    
 9.5-12.8  2.87  0.87-9.45 0.080 
  ≥12.9 4.86  1.43-16.50  0.010 
AD: Alzheimer’s disease, OR: odds ratio, CI: confidential interval,
MMSE: Mini-Mental State Examination.   
 
Table 3. Multivariate logistic regression analysis with moderate-
to-severe white matter change as the dependent variable in AD
patients 
Moderate-to-severe  
white matter change   
OR  95% CI  p 
Age (years) 1.08  0.99-1.19  0.09 
Being male  0.24  0.04-1.38  0.11 
Education (years) 0.91  0.76-1.09  0.29 
MMSE score  0.88  0.76-1.02  0.10 
Hypertension 2.39  0.69-8.33  0.17 
Homocysteine (μmol/L)  ≤9.4 1.00     
 9.5-12.8  2.72  0.63-11.83  0.18 
  ≥12.9 7.35  1.36-39.84  0.02 
AD: Alzheimer’s disease, OR: odds ratio, CI: confidential interval,
MMSE: Mini-Mental State Examination. 
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The association between higher plasma tHcy levels and 
moderate-to-severe WMC in AD suggests that the cause of 
the pathogenic process involving homocysteine is diffuse 
vascular damage. It has been shown that higher plasma tHcy 
levels in middle-aged women are an independent risk factor 
for lacunar infarcts, as observed using CT later in life,
30 and 
that elevated tHcy levels are associated with peripheral arterial 
disease.
31 The mechanism by which homocysteine might 
cause vascular damage is unclear. Experimental evidence 
suggests that homocysteine promotes atherogenesis by facil-
itating oxidative arterial injury, damaging the vascular matrix, 
and augmenting the proliferation of vascular smooth muscle.
32 
There are several theories as to the mechanisms by which 
vascular disorders influence the progress of AD. For exam-
ple, it is presumed that amyloid deposition is caused by a 
vascular disorder.
33 Alternatively, a vascular event may cause 
the progression of subclinical AD to a clinical stage.
34 Another 
potential mechanism through which tHcy could affect WMC 
in AD may be a failure of myelin synthesis through hypo-
methylation of post-transcriptional myelin basic protein.
35 
We found no significant correlation between MTA and 
plasma tHcy levels in the AD patients. In two reports, a cross-
sectional association has been described between plasma tHcy 
levels and hippocampal atrophy on MRI among nondement-
ed elderly subjects,
36,37 but a recent cohort study of a com-
munity-based sample did not confirm this association.
3 To 
our knowledge, the present study is the first to describe an 
association between higher plasma tHcy levels and MTA in 
AD patients. The MTA rating scale has been validated on T1-
weighted coronal images.
18 However, MTA was rated on T1- 
or T2-weighted coronal images in our study; therefore we 
cannot rule out the possibility that the MTA is exaggerated in 
some patients. 
Homocysteine has been shown to potentiate amyloid beta-
peptide-mediated toxicity in primary neuronal cultures.
17 Ex-
citotoxicity by homocysteine and its derivatives such as ho-
mocysteic acid and homocysteic sulfinic acid may occur via 
stimulation of N-methyl-D-aspartate receptors and subsequent 
damage to neuronal DNA, thus increasing the susceptibility 
to apoptotic cell death, as demonstrated in cultures of hip-
pocampal neurons.
38 However, it is unlikely that homocysteine 
would reach concentrations high enough to trigger direct neu-
rotoxic effects in vivo.
13 Homocysteine may not be neurotoxic 
by itself, but might enhance the brain’s vulnerability to con-
comitant neurotoxic stimuli such as beta amyloid.
39 Our find-
ing was not compatible with the notion that higher plasma 
levels of tHcy may contribute to the pathogenesis of AD via 
a direct neurotoxic effect. 
Our study has the limitations of including only a small 
sample and having a cross-sectional design. Therefore, we 
cannot state categorically whether higher plasma tHcy levels 
are a cause or a coexistent finding of moderate-to-severe 
WMC in AD. A long-term prospective study is needed to 
clarify this matter. 
The mechanism by which homocysteine may contribute to 
the pathogenesis of AD remains to be established. Our re-
sults support the theory that the vascular pathway can mediate 
the observed association between elevated plasma tHcy levels 
and AD. 
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